1. Home
  2. NAMSW vs OCCIO Comparison

NAMSW vs OCCIO Comparison

Compare NAMSW & OCCIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMSW
  • OCCIO
  • Stock Information
  • Founded
  • NAMSW N/A
  • OCCIO N/A
  • Country
  • NAMSW Netherlands
  • OCCIO United States
  • Employees
  • NAMSW 29
  • OCCIO N/A
  • Industry
  • NAMSW Biotechnology: Pharmaceutical Preparations
  • OCCIO Trusts Except Educational Religious and Charitable
  • Sector
  • NAMSW Health Care
  • OCCIO Finance
  • Exchange
  • NAMSW Nasdaq
  • OCCIO Nasdaq
  • Market Cap
  • NAMSW N/A
  • OCCIO N/A
  • IPO Year
  • NAMSW N/A
  • OCCIO N/A
  • Fundamental
  • Price
  • NAMSW $9.00
  • OCCIO $24.26
  • Analyst Decision
  • NAMSW
  • OCCIO
  • Analyst Count
  • NAMSW 0
  • OCCIO 0
  • Target Price
  • NAMSW N/A
  • OCCIO N/A
  • AVG Volume (30 Days)
  • NAMSW N/A
  • OCCIO N/A
  • Earning Date
  • NAMSW N/A
  • OCCIO N/A
  • Dividend Yield
  • NAMSW N/A
  • OCCIO N/A
  • EPS Growth
  • NAMSW N/A
  • OCCIO N/A
  • EPS
  • NAMSW N/A
  • OCCIO N/A
  • Revenue
  • NAMSW N/A
  • OCCIO N/A
  • Revenue This Year
  • NAMSW N/A
  • OCCIO N/A
  • Revenue Next Year
  • NAMSW N/A
  • OCCIO N/A
  • P/E Ratio
  • NAMSW N/A
  • OCCIO N/A
  • Revenue Growth
  • NAMSW N/A
  • OCCIO N/A
  • 52 Week Low
  • NAMSW N/A
  • OCCIO N/A
  • 52 Week High
  • NAMSW N/A
  • OCCIO N/A
  • Technical
  • Relative Strength Index (RSI)
  • NAMSW 47.49
  • OCCIO 54.30
  • Support Level
  • NAMSW $9.40
  • OCCIO $24.19
  • Resistance Level
  • NAMSW $10.14
  • OCCIO $24.32
  • Average True Range (ATR)
  • NAMSW 0.44
  • OCCIO 0.06
  • MACD
  • NAMSW -0.12
  • OCCIO -0.00
  • Stochastic Oscillator
  • NAMSW 24.31
  • OCCIO 73.33

About NAMSW NewAmsterdam Pharma Company N.V. Warrant

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About OCCIO OFS Credit Company Inc. 6.125% Series C Term Preferred Stock

OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.

Share on Social Networks: